조루 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 약제 유형별, 제형별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Premature Ejaculation Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Type, By Dosage Form, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,356,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,768,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,300,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 조루(PE) 치료 시장은 2024년 29억 5,000만 달러로 평가되었습니다. 2030년에는 46억 5,000만 달러에 달할 것으로 예상되며, 연평균 7.86%의 연평균 복합 성장률(CAGR)을 보일 전망입니다.

이러한 성장은 성 건강 문제에 대한 인식이 높아짐에 따라 치료의 발전이 이루어졌기 때문입니다. 조루은 남성의 가장 흔한 성기능 장애 중 하나이며, 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 성 건강에 대한 인식이 진화함에 따라 점점 더 많은 사람들이 PE와 같은 증상에 대해 전문가의 도움을 구하고 있습니다. 이러한 변화로 인해 의약품과 행동 요법을 포함한 치료 옵션이 확대되고 있습니다. 의료 서비스 제공업체들은 선택적 세로토닌 재흡수 억제제(SSRI)와 국소 마취 크림과 같은 비침습적 치료법 및 내복약을 포함한 보다 효과적인 새로운 치료법을 도입하고 있습니다. 치료법에 대한 인식이 높아짐에 따라 맞춤형 솔루션에 대한 수요가 증가함에 따라 시장은 꾸준히 성장하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	29억 5,000만 달러
시장 규모 : 2030년	46억 5,000만 달러
CAGR(2025-2030년)	7.86%
급성장 부문	온라인 약국
최대 시장	북미

시장 성장 촉진요인

의약품 혁신 증가

주요 시장 과제

부작용과 안전에 대한 우려

주요 시장 동향

환자 중심적 접근

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 조루 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 약제 유형별(Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors, Topical Anesthetics, Zertane)
  • 유형별(경구 요법, 국소 요법)
  • 제형별(정제, 스프레이)
  • 유통 채널별(병원, 온라인 약국, 소매 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 조루 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 조루 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 조루 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제9장 남미의 조루 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 조루 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 제품 출시
• 인수합병(M&A)

제13장 세계의 조루 치료 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 산업내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Absorption Pharmaceuticals Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Innovus Pharmaceuticals Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

제17장 전략적 제안

제18장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

The global premature ejaculation (PE) treatment market was valued at USD 2.95 billion in 2024 and is projected to reach USD 4.65 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.86%. This growth is attributed to advancements in treatments, fueled by a heightened awareness of sexual health issues. Premature ejaculation, one of the most common sexual dysfunctions in men, has led to an increasing demand for effective treatment options. As attitudes toward sexual health evolve, more individuals are seeking professional help for conditions like PE. This shift has expanded treatment options, including pharmaceuticals and behavioral therapies. Healthcare providers are introducing new, more effective treatments, including non-invasive therapies and oral medications, such as selective serotonin reuptake inhibitors (SSRIs) and local anesthetic creams. As awareness of available treatments increases, the market continues to experience consistent growth, driven by a demand for tailored solutions.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.95 Billion
Market Size 2030	USD 4.65 Billion
CAGR 2025-2030	7.86%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Key Market Drivers

Rising Pharmaceutical Innovation

Pharmaceutical companies are investing heavily in research and development to create medications specifically targeting premature ejaculation. For instance, dapoxetine, a selective serotonin reuptake inhibitor (SSRI), has been approved in multiple countries for PE treatment, offering targeted and effective options. These specialized medications have enhanced the efficacy of PE treatments, improving control over ejaculation timing and patient satisfaction. Ongoing developments in new medications aim to deliver better outcomes while reducing side effects, thereby improving patient compliance and comfort. Reducing side effects further enhances the appeal of treatments, as patients prefer therapies with minimal disruption to their daily lives.

Key Market Challenges

Side Effects and Safety Concerns

Certain pharmaceutical treatments for premature ejaculation, including SSRIs like dapoxetine, can cause side effects such as nausea, dizziness, headaches, and sexual side effects like reduced libido or erectile dysfunction. These side effects can reduce patient compliance and overall satisfaction. As medication responses vary from person to person, finding the most effective treatment can often involve a trial-and-error process, which can be frustrating for both patients and healthcare providers. Additionally, some individuals may have underlying health conditions or take medications that may interfere with PE treatments. Drug interactions are a concern, requiring healthcare providers to carefully assess potential risks. The long-term safety of certain treatments is not always well-established, and concerns about prolonged use may discourage some individuals from seeking or continuing treatment. Topical anesthetics, such as lidocaine creams, may also reduce sensation, affecting sexual pleasure for both partners.

Key Market Trends

Patient-Centric Approach

Healthcare providers are increasingly adopting patient-centric strategies by creating personalized treatment plans for individuals with PE. These plans take into account the severity of PE, underlying causes, medical history, and patient preferences. Patients are encouraged to actively participate in the decision-making process regarding their treatment options, leading to more collaborative and informed choices. The patient-centric approach emphasizes patient education and counseling, helping patients understand the condition, treatment options, potential side effects, and expected outcomes. Treatments may also include a holistic approach that addresses the physical, psychological, and emotional aspects of PE. Telemedicine and remote monitoring technologies are making it easier for patients to access care from home, enhancing convenience and accessibility while maintaining a patient-focused approach.

Key Market Players

• Absorption Pharmaceuticals Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Innovus Pharmaceuticals Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

Report Scope:

The Global Premature Ejaculation Treatment Market has been segmented as follows:

By Drug Type:

• Dapoxetine
• Phosphodiesterase Type 5 (PDE5) Inhibitors
• Selective Serotonin Reuptake Inhibitors
• Topical Anesthetics
• Zertane

By Treatment Type:

• Oral Therapies
• Topical Therapies

By Dosage Form:

• Pills
• Spray

By Distribution Channel:

• Hospitals
• Online Pharmacies
• Retail Pharmacies

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section includes detailed company profiles of the major players in the Global Premature Ejaculation Treatment Market.

Available Customizations:

TechSci Research offers customization of the report to meet specific business needs, including the addition of up to five extra company profiles for further insights into the competitive landscape.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Premature Ejaculation Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors, Topical Anesthetics, Zertane)
  • 5.2.2. By Type (Oral Therapies, Topical Therapies)
  • 5.2.3. By Dosage Form (Pills, Spray)
  • 5.2.4. By Distribution Channel (Hospitals, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Premature Ejaculation Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Type
  • 6.2.3. By Dosage Form
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Premature Ejaculation Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Dosage Form
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Premature Ejaculation Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Dosage Form
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Premature Ejaculation Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Dosage Form
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Premature Ejaculation Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Type
      • 6.3.4.2.3. By Dosage Form
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Premature Ejaculation Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Type
      • 6.3.5.2.3. By Dosage Form
      • 6.3.5.2.4. By Distribution Channel

7. Europe Premature Ejaculation Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Type
  • 7.2.3. By Dosage Form
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Premature Ejaculation Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Premature Ejaculation Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Premature Ejaculation Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Premature Ejaculation Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Dosage Form
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Premature Ejaculation Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Dosage Form
      • 7.3.5.2.4. By Distribution Channel

8. North America Premature Ejaculation Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Type
  • 8.2.3. By Dosage Form
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Premature Ejaculation Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Premature Ejaculation Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Premature Ejaculation Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Distribution Channel

9. South America Premature Ejaculation Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Type
  • 9.2.3. By Dosage Form
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Premature Ejaculation Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Premature Ejaculation Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Premature Ejaculation Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Premature Ejaculation Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Type
  • 10.2.3. By Dosage Form
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Premature Ejaculation Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Premature Ejaculation Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Premature Ejaculation Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Premature Ejaculation Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Absorption Pharmaceuticals Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Allergan PLC
• 16.3. AstraZeneca PLC
• 16.4. Bayer AG
• 16.5. Eli Lilly and Company
• 16.6. GlaxoSmithKline PLC
• 16.7. Innovus Pharmaceuticals Inc.
• 16.8. Merck & Co., Inc.
• 16.9. Pfizer, Inc.
• 16.10.Teva Pharmaceutical Industries Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료